Across TCGA pan-cancer cohorts, MYADM-AS1 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated MYADM-AS1 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MYADM-AS1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MYADM-AS1 expression acts as an unfavorable survival marker, although some lineages such as BRCA and UCS show a favorable association.

LIHC, CESC, and ACC are the cancer types where MYADM-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.418	0.603	<.001	71	view →
CESC	DFS	Tertile	All	0.752	0.888	<.001	62	view →
ACC	DFS	Median	IV	0.155	0.535	.001	59	view →
KIRP	OS	Quartile	II,III,IV	0.120	0.626	<.001	54	view →
LGG	DFS	Median	All	0.670	0.810	<.001	51	view →
BRCA	OS	Median	All	0.977	0.947	.002	35	view →
UCS	DFS	Tertile	II,III,IV	0.570	0.160	.002	32	view →
KIRC	DFS	Median	II,III,IV	0.441	0.627	.006	28	view →
CHOL	OS	Median	All	0.599	0.938	.015	23	view →
LUSC	DFS	Tertile	III,IV	0.378	0.654	.007	17	view →
READ	OS	Median	III,IV	0.946	0.296	.005	13	view →
THCA	DFS	Quartile	III,IV	0.764	0.945	.013	13	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

Exploration

Same gene, other analysis: MYADM-AS1 tumor-vs-normal RNA expression · all MYADM-AS1 data types